BERIRAB

Šalis: Izraelis

kalba: anglų

Šaltinis: Ministry of Health

Veiklioji medžiaga:

HUMAN-RABIES IMMUNOGLOBULIN

Prieinama:

CSL BEHRING LTD., ISRAEL

ATC kodas:

J06BB05

Vaisto forma:

SOLUTION FOR INJECTION

Sudėtis:

HUMAN-RABIES IMMUNOGLOBULIN 150 IU/ML

Vartojimo būdas:

I.M

Recepto tipas:

Required

Pagaminta:

CSL BEHRING GmbH, GERMANY

Farmakoterapinė grupė:

RABIES IMMUNOGLOBULIN

Gydymo sritis:

RABIES IMMUNOGLOBULIN

Terapinės indikacijos:

Prophylaxis of rabies.

Leidimo data:

2014-05-31

Prekės savybės

ע עבקנ הז ןולע טמרופ
"
לע רשואו קדבנ ונכותו תואירבה דרשמ י
-
ודי
PACKAGE INSERT
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE.
- Keep this leaflet. You may need to read it again.
- If you have further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to
others. It may harm
them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side
effects not listed in
this leaflet, please tell your doctor or pharmacist.
BERIRAB
Solution for injection for intramuscular use
ACTIVE INGREDIENT: Human rabies immunoglobulin.
PHARMACOTHERAPEUTIC GROUP
Immune sera and immunoglobulins, human rabies immunoglobulin
ATC-code: J06B B05
THERAPEUTIC INDICATIONS
Post-exposure prophylaxis of rabies infection after
●
exposure to scratches, bites or other injuries caused by a suspected
rabid animal
●
mucous membrane contamination with infectious tissue or saliva of a
suspected
rabid animal
●
contact of mucous membranes or newly skin injury with rabies live
attenuated
vaccine e.g. vaccination baits.
Human rabies immunoglobulin must always be used in combination with a
rabies
vaccine.
National and/or WHO guidelines regarding protection against rabies
should be
observed.
CONTRAINDICATIONS
Because of the life-threatening risk due to rabies, there are no
contraindications to
the administration of rabies immunoglobulin.
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Ensure that Berirab is not administered into a blood vessel because of
the risk of
shock.
True hypersensitivity reactions are rare. Berirab contains a small
quantity of IgA.
Individuals who are deficient in IgA have the potential for developing
IgA antibodies
and may have anaphylactic reactions after administration of blood
components
containing IgA.
Rarely human rabies immunoglobulin can induce a fall in blood pressure
with
anaphylactic reactions, even in patients who had tolerated previous
treatment w